Treatment of relapsed/refractory T cell neoplasms represents an unmet medical need. We recorded, retrospectively, data on 20 consecutive adult patients with T cell neoplasms (8 T cell lymphoma not otherwise specified (T-NOS), 4 angioimmunoblastic (AILT), 3 prolymphocytic leukemia (T-PLL), 3 advance-stage mycosis fungoides (MF) or Sézary syndrome (SS), and 2 T cell large granular lymphocytic leukemia (T-LGL)), treated with bendamustine. Partial (PR) and complete response (CR) rates were reached in nine (45 %) and two (10 %) patients, respectively, including three PR in T-NOS, one CR in AILT, three PR in T-PLL, two PR in MF/SS, and one CR and one PR in T-LGL lymphoma. The 6 months estimated progression free and overall survival was 44 and 67 %, respectively. Grade 3-4 neutropenia and thrombocytopenia were registered in 44 and 25 % of cases. Four patients developed major infectious complications. At a median follow-up of 6 months (range 1-18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms.

Bendamustine salvage therapy for T cell neoplasms / Zaja, Francesco; Baldini, Luca; Ferreri, Andrés J. M; Luminari, Stefano; Grossi, Alberto; Salvi, Flavia; Zambello, Renato; Goldaniga, Maria; Volpetti, Stefano; Fanin, Renato. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - STAMPA. - 92:9(2013), pp. 1249-1254. [10.1007/s00277-013-1746-9]

Bendamustine salvage therapy for T cell neoplasms

BALDINI, Luca;LUMINARI, Stefano;
2013

Abstract

Treatment of relapsed/refractory T cell neoplasms represents an unmet medical need. We recorded, retrospectively, data on 20 consecutive adult patients with T cell neoplasms (8 T cell lymphoma not otherwise specified (T-NOS), 4 angioimmunoblastic (AILT), 3 prolymphocytic leukemia (T-PLL), 3 advance-stage mycosis fungoides (MF) or Sézary syndrome (SS), and 2 T cell large granular lymphocytic leukemia (T-LGL)), treated with bendamustine. Partial (PR) and complete response (CR) rates were reached in nine (45 %) and two (10 %) patients, respectively, including three PR in T-NOS, one CR in AILT, three PR in T-PLL, two PR in MF/SS, and one CR and one PR in T-LGL lymphoma. The 6 months estimated progression free and overall survival was 44 and 67 %, respectively. Grade 3-4 neutropenia and thrombocytopenia were registered in 44 and 25 % of cases. Four patients developed major infectious complications. At a median follow-up of 6 months (range 1-18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms.
92
9
1249
1254
Bendamustine salvage therapy for T cell neoplasms / Zaja, Francesco; Baldini, Luca; Ferreri, Andrés J. M; Luminari, Stefano; Grossi, Alberto; Salvi, Flavia; Zambello, Renato; Goldaniga, Maria; Volpetti, Stefano; Fanin, Renato. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - STAMPA. - 92:9(2013), pp. 1249-1254. [10.1007/s00277-013-1746-9]
Zaja, Francesco; Baldini, Luca; Ferreri, Andrés J. M; Luminari, Stefano; Grossi, Alberto; Salvi, Flavia; Zambello, Renato; Goldaniga, Maria; Volpetti, Stefano; Fanin, Renato
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1064420
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 23
social impact